Sugi Predict

Sugi Predict / Compounds / SCHEMBL7176973

SCHEMBL7176973

SCHEMBL7176973

COc1cccc(OC)c1C(=O)[PH](=O)c1c(Br)ccc(C(=O)c2ccccc2)c1Br

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ MAPK1 P28482 2/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ HPGD P15428 4/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ CYP2D6 P10635 2/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ LMNA P02545 5/20 0.41
▸ HTT P42858 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ CYP3A4 P08684 1/20 0.40
▸ RECQL P46063 1/20 0.40
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA7 P43166 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182247 0.92 MAPT (0.40) MAPTKDM4EHSD17B10MAPK1ALOX15
SCHEMBL7185476 0.90 LMNA (0.43) MAPTKDM4EHSD17B10MAPK1ALOX15
SCHEMBL7183115 0.84 MEN1 (0.38) MAPTKDM4EHSD17B10MAPK1ALOX15
SCHEMBL7177385 0.80 MAPT (0.45) MAPTKDM4EHSD17B10MAPK1ALOX15
SCHEMBL7184420 0.80 MEN1 (0.39) MAPTKDM4EHPGDLMNASMN1; SMN2
SCHEMBL7189270 0.80 RORC (0.36) MAPTLMNAKMT2ACYP3A4ALDH1A1
SCHEMBL7183550 0.79 NR1H2 (0.38) MAPTHSD17B10HPGDCYP1A2CYP2C19
SCHEMBL7186467 0.79 MAPT (0.44) MAPTKDM4EHSD17B10MAPK1ALOX15
SCHEMBL7182229 0.78 MEN1 (0.37) MAPTKDM4EMAPK1HPGDCYP1A2
SCHEMBL7187754 0.78 CA12 (0.45) MAPTKDM4EHSD17B10MAPK1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPT 4870/4885KDM4E 3226/4885HSD17B10 56/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPT 4859/4885KDM4E 2651/4885HSD17B10 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.